Chicago Clinical Trials Unit
芝加哥临床试验单位
基本信息
- 批准号:10305616
- 负责人:
- 金额:$ 118.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-02-01 至 2027-11-30
- 项目状态:未结题
- 来源:
- 关键词:AIDS clinical trial groupAIDS preventionAIDS/HIV problemAcquired Immunodeficiency SyndromeAddressAdolescentAdolescent Medicine Trials NetworkAdultAmericasAntibodiesAreaAwardBehavioralCaringChicagoCitiesClinicalClinical ResearchClinical Trials NetworkClinical Trials UnitCollaborationsCommunitiesCommunity ParticipationCost ControlCountyDevelopmentDisease remissionElderlyElementsEnsureEpidemicEthicsFundingGeographyHIVHIV diagnosisHIV vaccineHIV/TBHealthHealthcareHepatitisHepatitis BHomelessnessHot SpotHuman ResourcesInfrastructureInstitutionInterruptionInvestmentsLaboratoriesLatinxLeadershipMediatingMidwestern United StatesMonitorMorbidity - disease rateNational Institute of Allergy and Infectious DiseasePerformancePersonsPharmacy facilityPhasePopulationPopulation HeterogeneityPopulations at RiskPositioning AttributePregnant WomenPrevalencePreventionPrevention ResearchPrevention strategyProductivityProtocols documentationProviderPublic HealthRegulationResearchResearch EthicsResearch InfrastructureResearch PersonnelResearch PriorityResistanceResource SharingResourcesRightsRiskScienceScientific Advances and AccomplishmentsSiteSocial BehaviorStructureSystemTechnologyTestingTherapeuticTherapeutic Clinical TrialTissue SampleTuberculosisUnited States National Institutes of HealthUniversitiesWellness CenterWorkYouthantiretroviral therapybasebehavioral studyblack men who have sex with mencis-femaleclinical centerclinical research siteco-infectioncohesioncommunity based participatory researchcommunity engagementcomorbiditycookingdisenfranchised populationdrug-sensitiveeffective therapyepidemiology studyexperiencehigh riskinnovationmen who have sex with menmultidisciplinarymultimodalitynovelnovel therapeuticsoperationoutreachpre-exposure prophylaxisprogramsquality assuranceracial minorityresearch studysafety netsexual minoritysocialsynergismtransgendertreatment strategy
项目摘要
Project Summary. The Chicago Clinical Trials Unit (CCTU) is a consortium of four Clinical Research Sites
(CRSs) which will address two priority clinical research areas of the NIAID: 1) adult HIV/AIDS therapeutic
strategies, including novel therapeutics, HIV cure, noninfectious comorbidities, and infectious comorbidities
of hepatitis B and tuberculosis; and 2) integrated HIV prevention strategies, including novel long-acting ARV-
based HIV prevention agents and delivery systems for Pre-exposure Prophylaxis (PrEP), multi-purpose
prevention technologies, integrated biomedical and socio-behavioral HIV prevention strategies, and
collaborative protocols with the HIV Vaccines Network testing antibody-mediated prevention strategies. The
CCTU consists of four highly experienced and scientifically productive CRSs that are uniquely positioned to
develop, implement and adapt the clinical research priorities of the NIAID clinical research priority areas. The
CCTU has a proven track record and will continue its productivity through active engagement with a diverse
host of at-risk and HIV-impacted communities, participation in high impact, ground-breaking clinical research
studies, efficient management of resources and critical performance oversight of the clinical activities,
laboratories, and pharmacies. Compliance with all relevant rules and regulations is a priority of the
consortium. The CCTU includes CRSs and personnel that have long-term productive involvement with the
two research networks with which the CCTU is affiliated, and platforms for inter-network collaboration with
the other NIAID networks. The CRSs and their network affiliations are: Northwestern University (adult
HIV/AIDS therapeutic strategies); Rush University (adult HIV/AIDS therapeutic strategies); Trinity Health &
Wellness Center (adult HIV/AIDS therapeutic strategies); and The Ruth L. Rothstein CORE Center (HIV
prevention and adult HIV/AIDS therapeutic strategies). The cities of Chicago and Dallas, where the CRSs
are located, are in Cook and Dallas counties, two of the 48 “hot spots” counties where half of new HIV
diagnoses in the US were concentrated in 2016 and 2017. The aims of this proposal are: development,
implementation and adaptation of the clinical research program of the 1) Adult HIV/AIDS Therapeutics
Strategies Clinical Trials Network in four CRSs, and 2) HIV Prevention Network in one CRS, in synergy with
all CCTU elements, and 3) To ensure all CCTU research is relevant to HIV impacted populations and
ethical through dynamic engagement of the community in all phases of the research. The CCTU is
well-positioned to reach diverse populations and contribute significantly to the NIAID research agenda.
RELEVANCE: The phenomenal scientific advances in HIV/AIDS research over the past 35 years have in
large part been due to NIAID's high-impact therapeutic and prevention studies being performed by its clinical
trials units (CTUs). The CCTU will continue to respond rapidly to emerging clinical research needs, engage
constituents, and identify more effective treatment and prevention strategies.
项目摘要。芝加哥临床试验单位(CCTU)是一个由四个临床研究中心组成的联盟
(CRS)将解决NIAID的两个优先临床研究领域:1)成人艾滋病毒/艾滋病治疗
策略,包括新疗法、HIV治愈、非感染性合并症和感染性合并症
B型肝炎和结核病; 2)综合艾滋病毒预防战略,包括新型长效抗逆转录病毒药物,
基于艾滋病毒的预防剂和暴露前预防(PrEP)的输送系统,多用途
预防技术,综合生物医学和社会行为艾滋病毒预防战略,
与艾滋病毒疫苗网络的合作协议测试抗体介导的预防战略。的
CCTU由四个经验丰富,科学生产力的CRS组成,它们具有独特的定位,
制定,实施和调整NIAID临床研究优先领域的临床研究优先事项。的
CCTU拥有良好的往绩记录,并将通过积极参与多元化的
许多高危和受艾滋病毒影响的社区,参与影响力大、突破性的临床研究
研究、资源的有效管理和临床活动的关键绩效监督,
实验室和药房。遵守所有相关规则和条例是
财团中央反恐组包括社区服务中心和长期参与反恐工作的人员。
两个研究网络与中央反恐局是附属的,和平台的网络间合作,
其他的NIAID网络CRS及其网络附属机构是:西北大学(成人
艾滋病毒/艾滋病治疗战略);拉什大学(成人艾滋病毒/艾滋病治疗战略); Trinity Health &
健康中心(成人艾滋病毒/艾滋病治疗战略);和露丝L。罗斯坦核心中心(艾滋病毒
预防和成人艾滋病毒/艾滋病治疗战略)。在芝加哥和达拉斯,
位于库克县和达拉斯县,这是48个“热点”县中的两个县,
美国的确诊病例集中在2016年和2017年。该提案的目标是:发展,
实施和调整1)成人艾滋病毒/艾滋病治疗的临床研究方案
在四个社区服务中心建立临床试验网络,2)在一个社区服务中心建立艾滋病毒预防网络,与
3)确保所有CCTU的研究与受艾滋病毒影响的人群相关,
通过社区在研究的各个阶段的动态参与来实现道德。中央反恐组是
有能力接触不同的人群,并为NIAID研究议程做出重大贡献。
相关性:过去35年来,艾滋病毒/艾滋病研究取得了惊人的科学进步,
在很大程度上是由于NIAID的高影响力的治疗和预防研究正在进行的临床
试验单位(CTU)。CCTU将继续快速响应新兴的临床研究需求,
我们的目标是,制定更有效的治疗和预防策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Babafemi O Taiwo其他文献
Antiretroviral Therapy: Darunavir: An Overview of an HIV Protease Inhibitor Developed to Overcome Drug Resistance
抗逆转录病毒疗法:达芦那韦:为克服耐药性而开发的 HIV 蛋白酶抑制剂概述
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Babafemi O Taiwo;Charles B. Hicks - 通讯作者:
Charles B. Hicks
Babafemi O Taiwo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Babafemi O Taiwo', 18)}}的其他基金
Expansion of SARS-CoV-2 Testing Supplement, Chicago Clinical Trials Unit
芝加哥临床试验中心 SARS-CoV-2 检测补充的扩展
- 批准号:
10166472 - 财政年份:2020
- 资助金额:
$ 118.6万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10600549 - 财政年份:2018
- 资助金额:
$ 118.6万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10228282 - 财政年份:2018
- 资助金额:
$ 118.6万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10468148 - 财政年份:2018
- 资助金额:
$ 118.6万 - 项目类别:
Intensive Combination Approach to Rollback the Epidemic (iCARE) in Nigerian Adolescents
尼日利亚青少年抗击疫情的强化组合方法 (iCARE)
- 批准号:
10252943 - 财政年份:2018
- 资助金额:
$ 118.6万 - 项目类别:
Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria
扩大多学科神经艾滋病研究培训以改善尼日利亚的艾滋病毒治疗结果
- 批准号:
10462158 - 财政年份:2013
- 资助金额:
$ 118.6万 - 项目类别:
Expanded Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria
扩大多学科神经艾滋病研究培训以改善尼日利亚的艾滋病毒治疗结果
- 批准号:
9903485 - 财政年份:2013
- 资助金额:
$ 118.6万 - 项目类别:
相似海外基金
HIV/AIDS prevention and intervention: HIV surveillance methods, Per-exposure prophylaxis eligibility and HIV/STI testing behaviours among a cohort of people living with HIV.
HIV/艾滋病预防和干预:HIV 感染者群体中的 HIV 监测方法、每次暴露预防资格和 HIV/STI 检测行为。
- 批准号:
495195 - 财政年份:2023
- 资助金额:
$ 118.6万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10013921 - 财政年份:2020
- 资助金额:
$ 118.6万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10181081 - 财政年份:2020
- 资助金额:
$ 118.6万 - 项目类别:
UCLA AIDS Prevention and Treatment Clinical Trials Unit
加州大学洛杉矶分校艾滋病预防和治疗临床试验单位
- 批准号:
10166309 - 财政年份:2020
- 资助金额:
$ 118.6万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10597008 - 财政年份:2020
- 资助金额:
$ 118.6万 - 项目类别:
International Traineeships in AIDS Prevention Studies (ITAPS)
艾滋病预防研究国际培训(ITAPS)
- 批准号:
10386931 - 财政年份:2020
- 资助金额:
$ 118.6万 - 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
- 批准号:
9921510 - 财政年份:2019
- 资助金额:
$ 118.6万 - 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
- 批准号:
9753631 - 财政年份:2019
- 资助金额:
$ 118.6万 - 项目类别:
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment, and Care among Adolescents Living with HIV in Botswana
减少耻辱感,改善博茨瓦纳艾滋病毒感染青少年的艾滋病毒/艾滋病预防、治疗和护理
- 批准号:
10265667 - 财政年份:2019
- 资助金额:
$ 118.6万 - 项目类别:
Closing the Gap: Involving Indigenous Elders and youth in HIV/AIDS prevention using participatory filmmaking
缩小差距:利用参与式电影制作让土著老年人和青年参与艾滋病毒/艾滋病预防工作
- 批准号:
364681 - 财政年份:2017
- 资助金额:
$ 118.6万 - 项目类别: